Epigenetic Regulation of Hepatitis B Virus Replication by Moon, In Young & Kim, Jin-Wook
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Epigenetic Regulation of Hepatitis B Virus Replication
In Young Moon and Jin-Wook Kim
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.81711
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
I      Ji -   i
Additional infor ation is available at the end of the chapter
Abstract
Hepatitis B virus (HBV) is the most important cause of chronic viral hepatitis worldwide. 
The genome of HBV is 3.2 kb partially double-stranded DNA, which is translocated to 
the nuclei of infected hepatocytes and converted to complete double-stranded DNA, aka 
covalently closed circular DNA (cccDNA). Typical course of chronic HBV infection results 
in inactive carrier state with clearance of viral particles in the bloodstream. However, the 
cccDNA can be detected in the hepatocytes from inactive carriers by sensitive methods. 
It has been increasingly known that epigenetic mechanisms contribute to the control of 
HBV replication in the inactive stage of HBV infection. Histone modification and DNA 
methylation have been identified in the HBV cccDNA, leading to modification of tran-
scriptional activity. The understanding of epigenetic control of transcription will shed 
light on the development of new therapeutic strategy against HBV cccDNA.
Keywords: hepatitis B virus, covalently closed circular DNA, histone modification, 
inactive carrier
1. Introduction
Hepatitis B virus (HBV) is the most important cause of chronic viral hepatitis worldwide. 
About 240–350 million people are infected with HBV globally [1]. Development of potent 
nucleos(t)ide analogs (Nas) has revolutionized the treatment of HBV, but current treatment 
cannot eradicate the DNA genome of HBV, i.e., covalently closed circular DNA (cccDNA) 
from the nuclei of infected hepatocytes. Since there have been no innate clearing mechanisms 
identified for foreign double-stranded DNA in mammalian cells, theoretically HBV cccDNA 
in the liver stem cells will dilute out but persist indefinitely in some portion of the hepatocytes 
[2]. Therefore, prolonged use of current NA therapy is recommended without interruption, 
which is very costly.
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It has been known that transcriptional activity of HBV cccDNA varies according to the stage 
of natural history of chronic hepatitis B (CHB) [3, 4]. Interestingly, many patients with chronic 
hepatitis B are free from circulating HBV during the natural course despite the presence of 
HBV cccDNA in the infected nuclei [5]. These findings raise the possibility that replication 
of HBV is regulated at the transcriptional level. Genetic changes, i.e., DNA mutation, are 
an attractive explanation for the variable transcriptional activity since the reverse transcrip-
tase activity of HBV is error-prone. However, no universal mutations have been identified 
associated with transcriptional suppression [6]. Consequently, epigenetic control has been 
proposed as the mechanism of these variable transcriptional activities in CHB patients [7], 
and this article covers the current knowledge of epigenetic mechanisms contributing to the 
transcriptional control of HBV replication.
2. Organization of HBV cccDNA and its transcriptional control
Hepatitis B virus (HBV) is a partially double-stranded circular DNA virus [8]. The viral DNA 
goes into nuclei of infected hepatocytes where it is converted to cccDNA [8]. The cccDNA 
is a viral minichromosome, which takes the form of “beads-on-a-string” conformation of 
nucleosomal packaging [9], analogous to DNA packaging by mammalian nucleosome. HBV 
core protein and X protein along with histone H3 and H4 are components of HBV minichro-
mosome [9–11]. A variety of cellular transcription factors bind HBV cccDNA, which in turn 
control transcriptional activity of HBV promoters: the preC/pregenomic, S1, S2, and X promoters 
[12]. The core promoter initiates transcription of preC and pregenomic RNA, the template for 
the viral genome by reverse transcription. Ubiquitous transcription factors such as specificity 
protein 1 (SP1), nuclear factor kappa B (NF-κβ), activator protein 1 (AP-1), and liver-enriched 
transcription factors such as hepatocyte nuclear factor 3 (HNF3), CAAT enhancer-binding 
protein (C/EBP), and several nuclear receptors such as hepatocyte nuclear factor 4 (HNF4), 
peroxisome proliferator-activated receptors (PPAR) and retinoid X receptors (RXRα), farne-
soid acid receptor (FXR), small heterodimer partner (SHP), and testicular orphan receptor 4 
(TR4) can bind core promoter [13, 14].
3. Epigenetic control of HBV transcription: histone modification
As described above, ultrastructure of HBV cccDNA simulates that of mammalian nucleosome, 
suggesting the possibility of histone molecules as a main factor for transcriptional control [9]. 
Indeed, Pollicino et al. demonstrated the feasibility of HBV-associated histone modification as 
a major transcriptional regulator of HBV [11]. Genome-wise search for posttranslational mod-
ification (PTM) of HBV-infected liver cell lines has revealed that active marks of transcription 
such as H3K4me3, H3K27ac, and H3K122ac are abundant in active chromatin, especially in 
the core promoter region [19]. Interestingly, however, the repressive marks of transcription, 
i.e., H3K27me3 and H3K9me2, are depleted in the HBV cccDNA, suggesting that modified 
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histones regulate HBV transcription mainly in favor of active replication. Pol2 enrichment is 
co-localized at the H3K27me-enriched transcription start site of precore/pregenomic area, and 
treatment with interferon alpha reduces the active PTMs, also suggesting that active marks of 
histone modification contribute to the transcriptional activity of HBV.
Much is unknown regarding the effects of histone modification on the binding of these 
transcription factors. Hepatitis X protein (HBx) is the most studied modulator of HBV-
bound histone [20, 21]. HBx is bound to the cccDNA and enhance transcription by increas-
ing histone acetylation and recruiting cellular coactivators p300, CBP, and PCAF [22], 
by inhibiting protein arginine methyltransferase 1 and reducing H4 methylation [23]. 
HBx also increases histone acetylation and H3K4me3 and decreases HP1 binding and 
Histone change Modifier HBV response and mechanisms References
H3K4me3 MLL3 Activation (H3K4me modification of the NTCP promoter 
by MLL3 may facilitate HBV infection in vivo.)
[19, 30]
Zinc finger and 
homeoboxes (ZHX2)
Repression (ZHX2 inhibited trimethylation of H3K4. 
Overexpression of ZHX2 also decreases the acetylation 
levels of H3K27 and H3K122.)
[26]
H3K27ac EZH2 Activation (Knockdown of EZH2 resulted in upregulation 
of HBeAg and ABsAg, indicating a repressive function of 
EZH2 on HBV gene expression.)
[28, 31]
H3K122ac P300/CBP Activation [19, 32, 33]
AcH3/AcH4 
H3K4me3
HBx Activation [20–22, 24]
H4R3me2s PRMT5 Repression (PRMT5-mediated histone H4 dimethyl Arg3 
symmetric (H4R3me2s) represses cccDNA transcription.)
[28]
H3K9me3 SETDB1 Repression (upon HBV infection, cellular mechanisms 
involving SETDB1-mediated H3K9me3 and HP1 
induce silencing of HBV cccDNA transcription through 
modulation of chromatin structure.)
[24]
SIRT3 Repression (SIRT3 is a novel host factor epigenetically 
restricting HBV cccDNA transcription by acting 
cooperatively with histone methyltransferase.)
[25]
H3K27me3 Suz12 Repression (downregulation of Suz12 and Znf198 enhances 
HBV replication.)
[34]
H3K79me KDM2B Repression (KDM2B as an H3K79 demethylase and link its 
function to transcriptional repression via SIRT1-mediated 
chromatin silencing.)
[27]
etc BCP mutation Repression (BCP mutations decrease viral replication 
capacity possibly by modulating the acetylation and 
deacetylation of cccDNA-bound histones.)
[29]
IFNα Repression [19, 35, 36]
Table 1. Histone modification affecting HBV transcription.
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H3K9me3 on the cccDNA [24]. Other host transcription factors, mainly suppressors, that 
act via epigenetic control of HBV include SIRT3 [25], zinc finger and homeoboxes 2 (ZHX2) 
[26], KDM2B [27], protein arginine methyltransferase 5 (PRMT5) [28], and SETDB1 [24]. 
Interestingly, mutations in the basal core promoter are also reported to be associated with 
histone modification [29]. The effect of histone modification on HBV replication is sum-
marized in Table 1.
4. Epigenetic control of HBV transcription: cccDNA methylation
Isolation and testing of HBV cccDNA shows methylation not only of HBV DNA integrated in 
host chromosome [39, 40] but also of HBV cccDNA. Methylation is speculated to affect repli-
cative activity of HBV [38], and this hypothesis was confirmed in the hepatoma cell lines [41] 
and human liver tissue [15, 16]. HBV cccDNA has three CpG islands which harbor methyla-
tion in human liver and hepatoma cell lines [37, 38]. Methylation of HBV in the CpG islands 
of cccDNA is associated with suppressed transcriptional activity of HBV [15, 16] (for recent 
reviews, see [17, 18]). Especially, methylation of CpG island II is associated with reduced HBV 
replicability [42].
Although DNA methyltransferases, i.e., DNMT1, DNMT3a, and DNMT3b, are expressed in 
normal tissues [45], the level of expression is higher in HCC [46], which may explain the 
increased levels of methylation in hepatocellular carcinoma (HCC) compared to noncancer-
ous tissues [43, 44]. In addition, since the hepatic expression of DNMT3a and DNMT3b, the 
de novo methylators, increases with age [47], methylation of HBV may also increase with 
age [42], which might explain suppressed replicative activity of HBV in the later stage of 
natural history. Degree of methylation also depends on HBeAg positivity [15, 42] and degree 
of hepatic fibrosis [42].
The mechanism of HBV DNA methylation is still unknown (Table 2). From the specific pat-
terns of methylation in the HBV genome [42], it can be speculated that some kind of molecular 
chaperon (s) may guide the de novo methylation enzymes to the specific target sequence. HBx 
may play a role, because it recruits DNMT3A to the regulatory promoters [48]. Small RNAs 
may be a plausible candidate, as suggested by our in vitro study in which short hairpin RNA 
induced methylation of the target site in HBV [49].
HBV 
area
Modifier HBV replication References
CpG2 HBc Increased (The relative abundances of HBc binding to CpG island 2 were 
associated with the binding of CREB binding protein (CBP) and with 
hypomethylation in CpG island 2 of HBV cccDNA minichromosomes.)
[50]
CpG3 PEG-IFN Decreased (PEG-IFN treatment significantly increased methylation of HBV 
cccDNA in CpG island III.)
[51]
Table 2. Mechanisms of methylation in HBV cccDNA.
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5. Therapeutic implications and future perspectives of epigenetics in 
chronic hepatitis B
NAs, the most commonly used modality of CHB therapy, is costly without definite duration. 
Interferon induces sustained virologic response with finite duration, but the response rate is 
suboptimal. The realistic goal of CHB therapy is to render the patients to the clinical situation 
similar to inactive carrier stage, i.e., normal alanine aminotransferase levels with low or nega-
tive serum HBV DNA levels. Since epigenetic silencing may contribute to the suppressive 
HBV replication status of inactive carrier stage, it would be theoretically feasible and clini-
cally useful to induce epigenetic suppression of HBV replication simulating natural inactive 
stage of disease. Further studies will be needed to elucidate the mechanisms and long-term 
consequences of epigenetic suppression of HBV replication.
6. Conclusions
Epigenetic modification is an important mechanism of host-viral interaction in the transcrip-
tional control of HBV. Current treatment strategy focuses on the inactivation/elimination of 
HBV cccDNA [17, 52], and knowledge on the epigenetic control is prerequisite for the novel 
development of HBV cure in the foreseeable future.
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